Targeting recipient dendritic cells with sialic acid-modified donor alloantigen prolongs skin

Lists

Sen, Monica, Peng, Qi, Ratnasothy, Kulachelvy, Ambrosini, Martino, Kalay, Hakan, Bazoer, Jordan, Adams, Kate E., El Ouazzani, Nouhad, Ababou, Abdessamad, Guiliano, David B., Saldana, Jose I., van Kooyk, Yvette, Lombardi, Giovanna and Smyth, Lesley (2025) Targeting recipient dendritic cells with sialic acid-modified donor alloantigen prolongs skin. International Journal of Molecular Sciences, 26 (13).

Preview

PDF (PDF/A)
Targeting recipient dendritic cells with sialic acid-modified_SmythL_accessible.pdf - Published Version
Available under License Creative Commons Attribution.
Download (1MB) | Preview

Official URL: https://www.mdpi.com/1422-0067/26/13/6168

Abstract

Mature dendritic cells (DCs) are known to activate effector immune responses, whereas steady state immature DCs can induce tolerance. Several studies have targeted immature murine quiescent DCs in vivo with antigen, including donor alloantigens, for the induction of tolerance. Receptors expressed by specific DC subsets have been also targeted with antibodies linked with antigens to induce tolerance; for instance, in vivo targeting of the DCIR2+ DC subset with donor alloantigen resulted in long-term survival of heart and skin transplants. DCs also express sialic acid immunoglobulin-like lectin (Siglec) receptors, and these have been successfully targeted with myelin oligiodendrocyte glycoprotein (MOG) antigen to induce tolerance in experimental autoimmune encephalomyelitis (EAE). We investigated, in a mismatched model of skin transplant (B6Kd into B6 recipient mice), whether targeting a sialylated alloantigen Kd (Sia-Kd) to Siglecs on recipient DCs promoted transplant survival. The injection of α2,3 Sia-Kd into B6 recipient mice prior to B6Kd skin transplantation, by binding to Batf3 dependent DCs, resulted in prolonged skin graft survival and an increase in CD4+CD62L+Foxp3+ Tregs. Targeting Siglecs on DC subsets in vivo represents a novel way of improving transplant survival.

Item Type:	Article
Identifier:	10.3390/ijms26136168
Keywords:	tolerance; dendritic cells; siglecs; allorecognition
Subjects:	Natural sciences > Cell and molecular biology
Depositing User:	Lesley Smyth
Date Deposited:	08 Jul 2025 12:28
Last Modified:	08 Jul 2025 12:45
URI:	https://repository.uwl.ac.uk/id/eprint/13839
Sustainable Development Goals:	Goal 3: Good Health and Well-Being

Downloads

Downloads per month over past year

Actions (login required)

View Item

References

Segura, E. Human dendritic cell subsets: An updated view of their ontogeny and functional specialization. Eur. J. Immunol. 2022,
52, 1759–1767.
Giza, H.M.; Bozzacco, L. Unboxing dendritic cells: Tales of multi-faceted biology and function. Immunology 2021, 164, 433–449.
Eisenbarth, S.C. Dendritic cell subsets in T cell programming: Location dictates function. Nat. Rev. Immunol. 2019, 19, 89–103.
4. Boardman, D.A.; Jacob, J.; Smyth, L.A.; Lombardi, G.; Lechler, R.I. What Is Direct Allorecognition? Curr. Transplant. Rep. 2016, 3,
275–283.
5. Lechler, R.I.; Batchelor, J.R. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor
strain dendritic cells. J. Exp. Med. 1982, 155, 31–41.
6. Liu, Z.; Braunstein, N.S.; Suciu-Foca, N. T cell recognition of allopeptides in context of syngeneic MHC. J. Immunol. 1992, 148,
35–40.
7. Benichou, G.; Takizawa, P.A.; Olson, C.A.; McMillan, M.; Sercarz, E.E. Donor major histocompatibility complex (MHC) peptides
are presented by recipient MHC molecules during graft rejection. J. Exp. Med. 1992, 175, 305–308.
8. Smyth, L.A.; Lechler, R.I.; Lombardi, G. Continuous Acquisition of MHC:Peptide Complexes by Recipient Cells Contributes to
the Generation of Anti-Graft CD8+ T Cell Immunity. Am. J. Transplant. 2017, 17, 60–68.
9. Benichou, G.;Wang, M.; Ahrens, K.; Madsen, J.C. Extracellular vesicles in allograft rejection and tolerance. Cell. Immunol. 2020,
349, 104063.
10. Li, B.; Lu, C.; Oveissi, S.; Song, J.; Xiao, K.; Zanker, D.; Duan, M.; Chen, J.; Xu, H.; Zou, Q.; et al. Host CD8α+ and CD103+
dendritic cells prime transplant antigen-specific CD8+ T cells via cross-dressing. Immunol. Cell Biol. 2020, 98, 563–576.
11. Hughes, A.D.; Zhao, D.; Dai, H.; Abou-Daya, K.I.; Tieu, R.; Rammal, R.; Williams, A.L.; Landsittel, D.P.; Shlomchik, W.D.; Morelli,
A.E.; et al. Cross-dressed dendritic cells sustain effector T cell responses in islet and kidney allografts. J. Clin. Investig. 2020, 130,
287–294.
12. Henry, E.; Desmet, C.J.; Garzé, V.; Fiévez, L.; Bedoret, D.; Heirman, C.; Faisca, P.; Jaspar, F.J.; Gosset, P.; Jacquet, A.P.A.; et al.
Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J.
Immunol. 2008, 181, 7230–7242.
13. Taner, T.; Hackstein, H.; Wang, Z.; Morelli, A.E.; Thomson, A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells
induce ag-specific T cell regulation and prolong graft survival. Am. J. Transplant. 2005, 5, 228–236.
14. Lee, J.-H.; Park, C.-S.; Jang, S.; Kim, J.-W.; Kim, S.-H.; Song, S.; Kim, K.; Lee, C.-K. Tolerogenic dendritic cells are efficiently
generated using minocycline and dexamethasone. Sci. Rep. 2017, 7, 15087.

15. Smyth, L.A.; Ratnasothy, K.; Moreau, A.; Alcock, S.; Sagoo, P.; Meader, L.; Tanriver, Y.; Buckland, M.; Lechler, R.; Lombardi, G.
Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs. J.
Immunol. 2013, 190, 4848–4860.
16. Bhatt, S.; Qin, J.; Bennett, C.; Qian, S.; Fung, J.J.; Hamilton, T.A.; Lu, L. All-trans retinoic acid induces arginase-1 and inducible
nitric oxide synthase-producing dendritic cells with T cell inhibitory function. J. Immunol. 2014, 192, 5098–5108.
17. Buckland, M.; Jago, C.B.; Fazekasova, H.; Scott, K.; Tan, P.H.; George, A.J.T.; Lechler, R.; Lombardi, G. Aspirin-treated human
DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am. J. Transplant. 2006, 6,
2046–2059.
18. Song, S.-S.; Yuan, P.-F.; Chen, J.-Y.; Fu, J.-J.; Wu, H.-X.; Lu, J.T.; Wei, W. TGF-β favors bone marrow-derived dendritic cells to
acquire tolerogenic properties. Immunol. Investig. 2014, 43, 360–369.
19. Moreau, A.; Vandamme, C.; Segovia, M.; Devaux, M.; Guilbaud, M.; Tilly, G.; Jaulin, N.; Le Duff, J.; Cherel, Y.; Deschamps, J.-Y.;
et al. Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer.
Mol. Ther. Methods Clin. Dev. 2014, 1, 14028.
20. Liu, X.; Sun, Y.; Zheng, Y.; Zhang, M.; Jin, X.; Kang, K.; Wang, Y.; Li, S.; Zhang, H.; Zhao, Q.; et al. Administration of Interleukin-
35-Conditioned Autologous Tolerogenic Dendritic Cells Prolong Allograft Survival After Heart Transplantation. Cell. Physiol.
Biochem. 2018, 49, 1180–1196.
21. Morante-Palacios, O.; Fondelli, F.; Ballestar, E.; Martínez-Cáceres, E.M. Tolerogenic Dendritic Cells in Autoimmunity and
Inflammatory Diseases. Trends Immunol. 2021, 42, 59–75.
22. Suuring, M.; Moreau, A. Regulatory Macrophages and Tolerogenic Dendritic Cells in Myeloid Regulatory Cell-Based Therapies.
Int. J. Mol. Sci. 2021, 22, 7970.
23. Hill, M.; Thebault, P.; Segovia, M.; Louvet, C.; Bériou, G.; Tilly, G.; Merieau, E.; Anegon, I.; Chiffoleau, E.; Cuturi, M.-C. Cell
therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and epstein-barr
virus-induced gene 3. Am. J. Transplant. 2011, 11, 2036–2045.
24. Sawitzki, B.; Harden, P.N.; Reinke, P.; Moreau, A.; Hutchinson, J.A.; Game, D.S.; Tang, Q.; Guinan, E.C.; Battaglia, M.; Burlingham,
W.J.; et al. Regulatory cell therapy in kidney transplantation (The ONE Study): A harmonised design and analysis of seven
non-randomised, single-arm, phase 1/2A trials. Lancet 2020, 395, 1627–1639.
25. Moreau, A.; Kervella, D.; Bouchet-Delbos, L.; Braudeau, C.; Saïagh, S.; Guérif, P.; Limou, S.; Moreau, A.; Bercegeay, S.; Streitz, M.;
et al. A Phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients. Kidney Int.
2023, 103, 627–637.
26. Castenmiller, C.; Keumatio-Doungtsop, B.-C.; van Ree, R.; de Jong, E.C.; van Kooyk, Y. Tolerogenic Immunotherapy: Targeting
DC Surface Receptors to Induce Antigen-Specific Tolerance. Front. Immunol. 2021, 12, 643240.
27. Tanriver, Y.; Ratnasothy, K.; Bucy, R.P.; Lombardi, G.; Lechler, R. Targeting MHC class I monomers to dendritic cells inhibits the
indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival. J. Immunol.
2010, 184, 1757–1764.
28. Yamazaki, S.; Dudziak, D.; Heidkamp, G.F.; Fiorese, C.; Bonito, A.J.; Inaba, K.; Nussenzweig, M.C.; Steinman, R.M. CD8+ CD205+
splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 2008, 181, 6923–6933.
29. Lübbers, J.; Rodríguez, E.; van Kooyk, Y. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions. Front. Immunol.
2018, 9, 2807.
30. Crocker, P.R.; Paulson, J.C.; Varki, A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 2007, 7, 255–266.
31. Macauley, M.S.; Crocker, P.R.; Paulson, J.C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol.
2014, 14, 653–666.
32. Keumatio Doungtsop, B.-C.; Nardini, E.; Kalay, H.; Versteeg, S.A.; Lübbers, J.; van Barneveld, G.; Li, E.R.J.; van Vliet, S.J.; van Ree,
R.; de Jong, E.C.; et al. Sialic acid-modified der p 2 allergen exerts immunomodulatory effects on human PBMCs. J. Allergy Clin.
Immunol. Glob. 2024, 3, 100193.
33. Pillai, S.; Netravali, I.A.; Cariappa, A.; Mattoo, H. Siglecs and immune regulation. Annu. Rev. Immunol. 2012, 30, 357–392.

34. Borges, T.J.; Lima, K.; Gassen, R.B.; Liu, K.; Ganchiku, Y.; Ribas, G.T.; Liao, M.; Goncalves, J.I.B.; Lape, I.T.; Rosales, I.A.; et al. The
inhibitory receptor Siglec-E controls antigen-presenting cell activation and T cell-mediated transplant rejection. Sci. Transl. Med.
2025, 17, eads2694.
35. Loschko, J.; Heink, S.; Hackl, D.; Dudziak, D.; Reindl,W.; Korn, T.; Krug, A.B. Antigen targeting to plasmacytoid dendritic cells
via Siglec-H inhibits Th cell-dependent autoimmunity. J. Immunol. 2011, 187, 6346–6356.
36. Perdicchio, M.; Ilarregui, J.M.; Verstege, M.I.; Cornelissen, L.A.M.; Schetters, S.T.T.; Engels, S.; Ambrosini, M.; Kalay, H.; Veninga,
H.; den Haan, J.M.M.; et al. Sialic acid-modified antigens impose tolerance via inhibition of T-
37. Bax, M.; Unger,W.; Kaur Singh, S.; McKenzie, E.J.; Litjens, M.; Garcia-Vallejo, J.J.; Saeland, E.; van Vliet, S.J.; Crocker, P.R.; van
Kooyk, Y. Targeting siglec-E on murine dendritic cells inhibits antigen presentation and CD4 and CD8 t cell responses. Ann.
Rheum. Dis. 2010, 69, A42.
38. Honjo, K.; Yan Xu, X.; Kapp, J.A.; Bucy, R.P. Evidence for cooperativity in the rejection of cardiac grafts mediated by CD4 TCR Tg
T cells specific for a defined allopeptide. Am. J. Transplant. 2004, 4, 1762–1768.
39. Brennan, T.V.; Jaigirdar, A.; Hoang, V.; Hayden, T.; Liu, F.-C.; Zaid, H.; Chang, C.K.; Bucy, R.P.; Tang, Q.; Kang, S.-M. Preferential
priming of alloreactive T cells with indirect reactivity. Am. J. Transplant. 2009, 9, 709–718.
40. Wang, J.; Manni, M.; Bärenwaldt, A.; Wieboldt, R.; Kirchhammer, N.; Ivanek, R.; Stanczak, M.; Zippelius, A.; König, D.; Rodrigues
Manutano, N.; et al. Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer. Front.
Cell Dev. Biol. 2022, 10, 828916.
41. Angata, T.; Hingorani, R.; Varki, N.M.; Varki, A. Cloning and characterization of a novel mouse Siglec, mSiglec-F: Differential
evolution of the mouse and human (CD33) Siglec-3-related gene clusters. J. Biol. Chem. 2001, 276, 45128–45136.
42. Ding, Y.; Guo, Z.; Liu, Y.; Li, X.; Zhang, Q.; Xu, X.; Gu, Y.; Zhang, Y.; Zhao, D.; Cao, X. The lectin Siglec-G inhibits dendritic cell
cross-presentation by impairing MHC class I-peptide complex formation. Nat. Immunol. 2016, 17, 1167–1175.
43. Hildner, K.; Edelson, B.T.; Purtha,W.E.; Diamond, M.; Matsushita, H.; Kohyama, M.; Calderon, B.; Schraml, B.U.; Unanue, E.R.;
Diamond, M.S.; et al. Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science 2008,
322, 1097–1100.
44. Mayer, C.T.; Ghorbani, P.; Nandan, A.; Dudek, M.; Arnold-Schrauf, C.; Hesse, C.; Berod, L.; Stüve, P.; Puttur, F.; Merad, M.; et al.
Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 2014,
124, 3081–3091.
45. Naik, S.H.; Sathe, P.; Park, H.-Y.; Metcalf, D.; Proietto, A.I.; Dakic, A.; Carotta, S.; O’Keeffe, M.; Bahlo, M.; Papenfuss, A.; et al.
Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo.
Nat. Immunol. 2007, 8, 1217–1226.
46. Marín, E.; Cuturi, M.C.; Moreau, A. Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand? Front.
Immunol. 2018, 9, 274.
47. Bain, C.C.; Montgomery, J.; Scott, C.L.; Kel, J.M.; Girard-Madoux, M.J.H.; Martens, L.; Zangerle-Murray, T.F.P.; Ober-Blöbaum, J.;
Lindenbergh-Kortleve, D.; Samsom, J.N.; et al. TGFβR signalling controls CD103+CD11b+ dendritic cell development in the
intestine. Nat. Commun. 2017, 8, 620.
48. Tateyama, H.; Murase, Y.; Higuchi, H.; Inasaka, Y.; Kaneoka, H.; Iijima, S.; Nishijima, K. Siglec-F is induced by granulocyte–
macrophage colony-stimulating factor and enhances interleukin-4-induced expression of arginase-1 in mouse macrophages.
Immunology 2019, 158, 340–352.
49. Idoyaga, J.; Fiorese, C.; Zbytnuik, L.; Lubkin, A.; Miller, J.; Malissen, B.; Mucida, D.; Merad, M.; Steinman, R.M. Specialized role of
migratory dendritic cells in peripheral tolerance induction. J. Clin. Investig. 2013, 123, 844–854.
50. Li, R.-J.E.; de Haas, A.; Rodríguez, E.; Kalay, H.; Zaal, A.; Jimenez, C.R.; Piersma, S.R.; Pham, T.V.; Henneman, A.A.; de Goeij-de
Haas, R.R.; et al. Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After α2-3-Linked
Sialic Acid Ligand Binding. Front. Immunol. 2021, 12, 673454.
51. Lübbers, J.; Eveline Li, R.-J.; Gorki, F.S.; Bruijns, S.C.M.; Gallagher, A.; Kalay, H.; Ambrosini, M.; Molenaar, D.; Van den Bossche,
J.; van Vliet, S.J.; et al. α2-3 Sialic acid binding and uptake by human monocyte-derived dendritic cells alters metabolism and
cytokine release and initiates tolerizing T cell programming. Immunother. Adv. 2021, 1, ltab012.

Tools

CORE (COnnecting REpositories)

The University of West London

Targeting recipient dendritic cells with sialic acid-modified donor alloantigen prolongs skin

Abstract

Downloads

Actions (login required)

Menu